Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
358 studies found for:    "Alkylating Agents" | Studies updated in the last 30 days
Show Display Options
Rank Status Study
1 Completed Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
2 Recruiting Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Cyclophosphamide;   Drug: Azathioprine;   Drug: Methylprednisolone
3 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
4 Not yet recruiting Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: Thoracic RT;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Nivolumab;   Other: Placebo
5 Recruiting Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Drug: Nivolumab;   Drug: Cisplatin;   Drug: Cetuximab;   Radiation: IMRT
6 Terminated Study of Intravenous RXDX-107 in Patients With Solid Tumors
Condition: Solid Tumor
Intervention: Drug: RXDX-107
7 Not yet recruiting Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Condition: Severe Aplastic Anemia
Interventions: Drug: Antithymocyte Globulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: UCB HSCT;   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
8 Not yet recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
9 Not yet recruiting Multi-Dose CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
10 Recruiting Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Conditions: Leukemia, Lymphoid;   Leukemia, Myeloid;   Myelodysplastic Syndromes;   Myelofibrosis;   Lymphoma, Malignant;   Multiple Myeloma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Biological: Rabbit ATG;   Drug: Methotrexate
11 Not yet recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
12 Not yet recruiting Carboplatin-cyclophosphamide Combined With Atezolizumab
Conditions: Breast Cancer;   Cervix Cancer;   Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: carbplatin, cyclophophamide, atezolizumab
13 Not yet recruiting Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Conditions: Primary Effusion Lymphoma;   B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
14 Recruiting Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Epirubicin 90 mg/m2 iv;   Drug: Cyclophosphamide 600 mg/m2 iv;   Drug: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv;   Drug: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only);   Drug: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only);   Dietary Supplement: Tocotrienol 300 mg x 3 daily
15 Recruiting Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Conditions: Multiple Myeloma;   Amyloidosis
Interventions: Device: Melphalan;   Drug: Pegfilgrastim;   Procedure: Autologous Hematopoietic Progenitor Cell Transplant
16 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
17 Recruiting Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;   Drug: pirarubicin and cyclophosphamide
18 Recruiting Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Conditions: Glioblastoma;   Malignant Glioma
Interventions: Drug: Marizomib;   Drug: Temozolomide;   Radiation: Radiation Therapy
19 Recruiting Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23
Condition: Ovarian Neoplasms
Interventions: Drug: Trabectedin;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Topotecan;   Drug: Gemcitabine;   Drug: Weekly Paclitaxel;   Drug: Carboplatin
20 Completed Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma
Condition: Glaucoma
Interventions: Procedure: Standard Guarded Trabeculectomy;   Drug: Mitomycin C;   Drug: Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years